In Brief: Conceptus
This article was originally published in The Gray Sheet
Executive Summary
Conceptus: ERA resectoscope sheath gets marketing go ahead from FDA for use in gynecological applications including endometrial resection and ablation, myomectomy (fibroid removal) and polypectomy. The single-use device is intended for use with existing electrosurgical systems "to enhance the safety of therapeutic hysteroscopy procedures," Conceptus states. Company President and CEO Kathryn Tunstall commented: "By enhancing the safety of therapeutic hysteroscopy procedures, and making the procedures less costly and less burdensome for the OR staff, we believe that ERA will encourage the adoption of therapeutic hysteroscopy as a viable, minimally invasive alternative" to hysterectomy...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.